Home » Topics » Regulatory » NMPA

NMPA
RSS

Phase II trials of F-351 begin in China

June 12, 2015

Arteether amine maleate cleared to enter clinical studies in China

May 26, 2015

China FDA clears IND for development of DP-VPA through phase III for epilepsy

April 16, 2015

China approves Epidaza for peripheral T-cell lymphoma

Jan. 13, 2015

Sirnaomics files Chinese IND application for STP-705 for hypertrophic scars

Jan. 7, 2015

China publishes draft biosimilar guidance

Nov. 18, 2014

DC Bead approved in China for tumor embolization

Aug. 28, 2014

UC MSCs show potential in clinical study for SLE

July 30, 2014

China's regulatory authority approves phase II trials of F-351

July 3, 2014

Chinese fast track designation granted to epilepsy drug DP-VPA

June 11, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...